P4078-01A-ML550
Conjugate
MaxLight™550Specificity
Recognizes human phosphorylated tyrosine residues. Does not crossreact with phosphorylated threonine or phosphorylated serine residues. Binding to phosphorylated tyrosine residues is inhibited by divalent cations at concentrations >1mM and salt concentrations >0.2M.Source Antibody
humanPurity
Purified by immunoaffinity chromatography.EU Commodity Code
30021010Shipping Temp
Blue IceStorage Temp
4°C Do Not FreezeNotes
Preservative Free
BSA Free
Phosphotyrosine (MaxLight 550)
Protein tyrosine phosphorylation has been the subject of intense investigation for over two decades. Tyrosine phosphorylation is catalyzed by members of the tyrosine kinase superfamily. To date, approximately 90 members of this superfamily have been identified in the human genome. Levels of phosphorylation of tyrosine residues within cellular proteins are observed to increase in response to growth factors, cytokines, insulin, extracellular matrix components and other stimuli. Tyrosine phosphorylation has several effects, including the regulation of enzyme activity, as well as the localization of enzyme activity through the generation of docking sites for proteins bearing SH2 domains.
Applications
Suitable for use in FLISA, Western Blot, Immunohistochemistry, Immunocytochemistry and Immunoprecipitation. Other applications not tested.
Recommended Dilutions
FLISA: 1:2000 Western Blot: 1:2000 Immunohistochemistry: 1:500 Immunocytochemistry: 1:500 Immunoprecipitation: 1:500 Optimal dilutions to be determined by the researcher.
Storage and Stability
Store product at 4°C in the dark. DO NOT FREEZE! Stable at 4°C for 12 months after receipt as an undiluted liquid. Dilute required amount only prior to immediate use. Further dilutions can be made in assay buffer. Caution: MaxLight™550 conjugates are sensitive to light. For maximum recovery of product, centrifuge the original vial prior to removing the cap.
Note: Applications are based on unconjugated antibody.
Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.
References
1. Druker, B.J., H.J. Mamon, and T.M. Roberts (1989) New Eng. J. Med. 321:1382-1391. 2. Frackelton, R.A., Jr., A.H. Ross, and H.N. Eisen (1983) Mol. Cell. Biol. 3:1343-1352. 3. Glenney, J.R., Jr., L. Zokas, and M.P. Kamps (1988) J. Immunol. Meth. 109:277-285. 4. Hanissian, S.H. and N. Sahyoun (1992) J. Neurosci. Res. 32(4):576-582. 5. Takagi, S., M. Daibata, T.J. Last, R.E. Humphreys, D.C. Parker, and T. Sairenji (1991) J. Exp. Med. 174(2):381-388. 6. Tremblay, L. and R. Beliveau (1994) Am. J. Physiol. 267(3 Pt 2):F415-F422. 7. Wang, J.Y.J. (1988) Anal. Biochem. 172:1-7.USBio References
No references available